Generalized Myasthenia Gravis Clinical Trials in Scottsdale, Arizona

4 studies are recruiting for generalized myasthenia gravis in Scottsdale, Arizona right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

    The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.

    Stage
    Phase 3
    Ages
    18 to 80
    Site
    Site Number - 1025, Scottsdale, Arizona
    Locations
    88 in total
    Run by
    Immunovant Sciences GmbH

    See if you can join NCT07039916 on ClinicalTrials.gov

  2. A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

    A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.

    Stage
    Phase 3
    Ages
    18 to 85
    Site
    Honor Health Research Institute, Scottsdale, Arizona
    Locations
    130 in total
    Run by
    Novartis Pharmaceuticals

    See if you can join NCT06744920 on ClinicalTrials.gov

  3. A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

    The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    HonorHealth Neurology - Bob Bové Neuroscience Institute, Scottsdale, Arizona
    Locations
    111 in total
    Run by
    Vor Biopharma

    See if you can join NCT06456580 on ClinicalTrials.gov

  4. Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

    Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).

    Stage
    Not phased
    Ages
    18 and older
    Site
    Clinical Trial Site, Scottsdale, Arizona
    Locations
    51 in total
    Run by
    Alexion Pharmaceuticals, Inc.

    See if you can join NCT04202341 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.